tetano
Editor, Senior Moderator
Int J Neurosci
. 2021 Feb 3;1-6.
doi: 10.1080/00207454.2021.1886097. Online ahead of print.
A Case of Guillain-Barr? Syndrome Related to COVID-19 Infection
?lk? T?rk B?r?[SUP] 1 [/SUP], Cansu K?seoğlu Toksoy[SUP] 1 [/SUP], Cem B?l?k[SUP] 2 [/SUP], Hayri Demirbaş[SUP] 1 [/SUP], Ahmet ?ağdaş Yılmaz[SUP] 3 [/SUP]
Affiliations
Abstract
After the first COVID-19 case, reported neurological complications are increasing day by day. In this paper, we present a benign-course Guillain-barre syndrome (GBS) emerging 2 weeks after COVID-19 infection in a 35-years-old male. Cough and fever were started 18 days ago and his PCR test was resulted positive for COVID-19 infection. After treatment and quarantine were completed, he developed sudden leg weakness following autonomic features. Cerebrospinal fluid was suggestive for GBS despite electrodiagnostic test was not helpful because it was done in the first days. He recovered without needing any immunotherapy. Our case suggested that COVID-19 can cause atypical benign GBS forms in addition to well-known variants. Comprehensive studies are needed to describe the unknowns and determine the exact prevalence of GBS after COVID-19 infection, including mild cases that did not require hospital admission.
Keywords: COVID-19; Guillain-barre syndrome; autoimmune; coronavirus; polyneuropathy.
. 2021 Feb 3;1-6.
doi: 10.1080/00207454.2021.1886097. Online ahead of print.
A Case of Guillain-Barr? Syndrome Related to COVID-19 Infection
?lk? T?rk B?r?[SUP] 1 [/SUP], Cansu K?seoğlu Toksoy[SUP] 1 [/SUP], Cem B?l?k[SUP] 2 [/SUP], Hayri Demirbaş[SUP] 1 [/SUP], Ahmet ?ağdaş Yılmaz[SUP] 3 [/SUP]
Affiliations
- PMID: 33535007
- DOI: 10.1080/00207454.2021.1886097
Abstract
After the first COVID-19 case, reported neurological complications are increasing day by day. In this paper, we present a benign-course Guillain-barre syndrome (GBS) emerging 2 weeks after COVID-19 infection in a 35-years-old male. Cough and fever were started 18 days ago and his PCR test was resulted positive for COVID-19 infection. After treatment and quarantine were completed, he developed sudden leg weakness following autonomic features. Cerebrospinal fluid was suggestive for GBS despite electrodiagnostic test was not helpful because it was done in the first days. He recovered without needing any immunotherapy. Our case suggested that COVID-19 can cause atypical benign GBS forms in addition to well-known variants. Comprehensive studies are needed to describe the unknowns and determine the exact prevalence of GBS after COVID-19 infection, including mild cases that did not require hospital admission.
Keywords: COVID-19; Guillain-barre syndrome; autoimmune; coronavirus; polyneuropathy.